News

BTK Inhibitor Orelabrutinib Demonstrates Efficacy, Safety for Patients With R/R Mantle Cell Lymphoma

09/29/2023

Orelabrutinib was effective and well-tolerated among patients with relapsed/refractory mantle cell lymphoma, according to a phase 1/2 study.

Orelabrutinib was effective and...

09/29/2023

Oncology

News

Parsaclisib Displayed Significant Clinical Benefit, Manageable Safety Among Patients With R/R MCL

09/28/2023

Jordan Kadish ;

Findings from the phase 2 CITADEL-205 trial indicated PI3Kδ inhibitor parsaclisib displayed significant clinical benefits and a manageable safety profile among patients with R/R mantle cell lymphoma.

Findings from the phase 2...

09/28/2023

Oncology

News

Prognostic Significance of Gene Polymorphisms for Patients With MCL and Indolent Non-Hodgkin Lymphomas After Bendamustine and Rituximab Treatment

09/26/2023

Jordan Kadish ;

Gene polymorphisms demonstrated prognostic value regarding disease outcomes for patients with indolent non-Hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab, according to findings from a 5-year follow-up study.

Gene polymorphisms demonstrated...

09/26/2023

Oncology

News

Allogeneic Stem Cell Transplantation Demonstrates Lasting Remissions Among Patients With MCL, Including With TP53 Mutations

09/22/2023

Jordan Kadish ;

Allogeneic stem cell transplantation demonstrated long-term remissions among patients with mantle cell lymphoma, including patients with TP53-mutated disease, according to an extended follow-up study.

Allogeneic stem cell...

09/22/2023

Oncology

News

Pirtobrutinib Demonstrated Durable Efficacy, Safety Among Patients With Covalent BTK Inhibitor-Pretreated MCL

09/18/2023

Jordan Kadish ;

According to the BRUIN trial, pirtobrutinib demonstrated encouraging efficacy and safety outcomes among patients with heavily pretreated mantle cell lymphoma following covalent BTK inhibitor treatment.

According to the BRUIN trial,...

09/18/2023

Oncology

News

Prognostic Value of CAR-HEMATOTOX Score for Treatment Outcomes of Patients With R/R MCL Undergoing CAR T-Cell Therapy

09/15/2023

Jordan Kadish ;

CAR-HEMATOTOX scores predicted treatment outcomes and toxicity risks among patients with R/R MCL treated with CAR T-cell therapy, according to a multicenter observational study.

CAR-HEMATOTOX scores predicted...

09/15/2023

Oncology

News

R-CHOP Plus R-BAC Shows Potential as Induction Therapy for Transplant-Eligible Patients With MCL

09/06/2023

Jordan Kadish ;

The combination of R-CHOP and R-BAC demonstrated efficacy as a potential induction therapy option for transplant-eligible patients with mantle cell lymphoma, according to a retrospective analysis.

The combination of R-CHOP and...

09/06/2023

Oncology

News

Prognostic Significance of Time to POD, Ki67, and MIPI for Patients With R/R Mantle Cell Lymphoma Initiating Second-Line BTK Inhibitor Therapy

08/08/2023

Jordan Kadish ;

Time to progression of disease, Ki67, and MIPI were strongly associated with survival outcomes among patients with R/R MCL undergoing treatment with second-line BTK inhibitors after rituximab-based chemotherapy.

Time to progression of disease,...

08/08/2023

Oncology

News

Sequential Bendamustine and Rituximab Plus Cytarabine and Rituximab Regimen With or Without Acalabrutinib Shows Promise for Patients With MCL

08/08/2023

Jordan Kadish ;

Induction regimens incorporating sequential rather than alternating bendamustine and rituximab plus cytarabine and rituximab sequentially demonstrated promising results among patients with mantle cell lymphoma, according to pooled data from 2...

Induction regimens incorporating...

08/08/2023

Oncology

News

Lenalidomide, Rituximab, and Venetoclax Combination Demonstrates Efficacy, Safety for Patients With Untreated MCL

07/18/2023

Jordan Kadish ;

The combination of lenalidomide, rituximab, and venetoclax yielded high efficacy and safety among patients with untreated mantle cell lymphoma.

The combination of lenalidomide,...

07/18/2023

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology